Melanoma trials in Spain

In Spain 51 Also abroad 579

51 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Where
Barcelona, Madrid, Murcia, Sabadell, Sevilla
Age
18 years and over
People
120 worldwide
Run by
Biocon Biologics UK PLC
See details and how to joinNCT07476326 · EU 2025-525158-20-00
Phase 1Taking people
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Where
Barcelona, Madrid
Age
18 years and over
People
250 worldwide
Run by
Pfizer
See details and how to joinNCT07519655
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Barcelona, Hospitalet, Madrid, Seville
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
Phase 4Taking people
Dabrafenib and/or Trametinib Rollover Study
Where
Barcelona, Madrid, Valencia
Age
18 years to 100 years
People
100 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Logrono
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 3Taking people
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
Where
Barcelona, Bilbao, Huelva, Lleida, Madrid, Málaga, Sabadell, Seville, Torrejón de Ardoz
Age
18 years and over
People
632 worldwide
Run by
mAbxience Research S.L.
See details and how to joinNCT07221734
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Barcelona, Madrid, Málaga, Seville, Valencia
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Sevilla
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
No phaseTaking people
Development and Multi-Centre Validation of a Novel Non-Invasive Melanoma Molecular Diagnostic Test
Where
Barcelona
Age
18 years and over
People
2,000 worldwide
Run by
Mitra Bio
See details and how to joinNCT07883954
Phase 1Taking people
A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III melanoma in the adjuvant setting
Where
Badajoz, Barcelona, Cáceres, Granada, Jerez De La Frontera, Las Palmas de Gran Canaria, Lleida, Madrid, Majadahonda, Málaga, Oviedo, Pozuelo de Alarcón, Sabadell, San Cristóbal de La Laguna, Santander, Sevilla, Torrejón de Ardoz, Valencia
Age
18 years and over
People
83 worldwide
Run by
H e x a l AG
See details and how to join2025-521919-39-00 · EU 2025-521919-39-00
Phase 1/2Taking people
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Where
Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Valencia
Age
18 years and over
People
1,438 worldwide
Run by
BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00
Phase 2/3Taking people
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Where
Badalona, Barcelona, Cáceres, Girona, Jerez de la Frontera, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Murcia, Santander, Santiago de Compostela, Valencia
Age
18 years and over
People
740 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00
Phase 2Not yet taking people in Spain
PHOENIX - ECP: Extracorporeal PHotopheresis for immune-related cOlitis and/or hEpatitis in advanced melaNoma with inadequate response to steroId eXposure
Where
Barcelona, Madrid, Murcia
Age
18 years and over
People
46 worldwide
Run by
Therakos Europe Limited
See details and how to join2026-526261-14-00 · EU 2026-526261-14-00
Phase 1Taking people
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Where
Barcelona, Logroño, Madrid
Age
18 years and over
People
124 worldwide
Run by
Pliant Therapeutics, Inc.
See details and how to joinNCT06270706
Phase 2Taking people
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Where
Barcelona, Madrid
Age
18 years and over
People
160 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06961006
Phase 3Taking people
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Santander, Sevilla, Valencia
Age
18 years to 70 years
People
670 worldwide
Run by
Iovance Biotherapeutics, Inc.
See details and how to joinNCT05727904 · EU 2022-503140-41-00
Phase 1/2Taking people
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Where
Barcelona, Madrid
Age
18 years and over
People
250 worldwide
Run by
BioInvent International AB
See details and how to joinNCT04752826 · EU 2023-509847-29-00
Phase 2Taking people
Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma
Where
L'Hospitalet de Llobregat, Madrid, Valencia
Age
18 years and over
People
19 worldwide
Run by
Grupo Español Multidisciplinar de Melanoma
See details and how to joinNCT07057596 · EU 2023-509076-42-00
No phaseTaking people
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Where
A Coruña, Barcelona, Girona, Las Palmas de Gran Canaria, Madrid, Málaga, Sabadell, Santiago de Compostela, Valencia
Age
18 years and over
People
2,285 worldwide
Run by
Guardant Health, Inc.
See details and how to joinNCT05059444
Phase 1Taking people
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Where
Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Seville, Valencia
Age
18 years and over
People
400 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT04913285
Phase 1Taking people
Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma
Where
Badalona, Barcelona, Cáceres, L'Hospitalet de Llobregat, Madrid, Málaga, Pozuelo de Alarcón, Sevilla
Age
18 years and over
People
120 worldwide
Run by
Alvotech Swiss AG
See details and how to joinNCT07475572 · EU 2025-525093-11-00
Phase 3Enrolling by invitation
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma
Where
L'hospitalet De Llobregat, Santiago de Compostela, Sevilla, Valencia
Age
18 years and over
People
100 worldwide
Run by
Aura Biosciences
See details and how to joinNCT07338968 · EU 2025-524405-33-00
Phase 1/2Taking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Badalona, Barcelona, Madrid, Málaga, Pamplona
Age
18 years and over
People
1,109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
Phase 1/2Taking people
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Where
Barcelona, Madrid, Valencia
Age
18 years and over
People
366 worldwide
Run by
Marengo Therapeutics, Inc.
See details and how to joinNCT05592626 · EU 2023-505334-10-01
Phase 1Taking people
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
Where
Barcelona, Madrid, Valencia
Age
18 years and over
People
106 worldwide
Run by
MonTa Biosciences ApS
See details and how to joinNCT04855435 · EU 2024-512294-26-00